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Objetives:  Underreporting  of work-related  cancer  in  the  Basque  Country  (Spain)  is  massive.  The  aim  of
our study  is  to estimate  the  job-related  cancer  in the  Basque  Country  in 2008  treated  by  the  Basque  Public
Health  System-Osakidetza,  as  well  as  the  medical  costs  derived  from  its  treatment  in the  same  year.
Methods:  Scientiﬁc  evidence  from  industrialised  countries  is used  to estimate  the  number  of  processes
of  cancer  attributable  to  work.  Medical  costs  for  specialised  care  (outpatient  and  hospital  admissions)
are  derived  from  the National  Health  System  cost  accounts.  Costs  due  to primary  health  care and  phar-
maceutical  beneﬁts  are  obtained  from  Spanish  secondary  sources.  Figures  were  computed  according  to
disease and  sex.
Results: We  estimate  1,331  work-attributable  cancers  hospitalizations  and  229  work-attributable  cancers
specialized  ambulatory  cases.  Medical  costs  borne  by public  health  care  system  exceed  10 million  euros.
Specialized  care  accounts  for 64.2%  of the  total  cost.  Bronchus  and  lung  cancer  represents  the  largest
percentage  of total  expenditure  (27%),  followed  by  the  bladder  cancer  (12.6%),  mesothelioma  (8.6%),  the
colon cancer  (7.3%),  and  stomach  (6.7%).
Conclusions:  The  magnitude  of cancer  attributable  to work  in the  Basque  Country  is  much  higher  than
reﬂected  in  the ofﬁcial  Registry  of  Occupational  Diseases.  Underreporting  of  work-related  cancers  ham-
pers prevention  and  shifts  funding  of  medical  costs  from  social  security  to  the  tax-ﬁnanced  public  health
system.
©  2012  SESPAS.  Published  by Elsevier  España,  S.L.  All rights  reserved.
Costes  sanitarios  directos  del  cáncer  atribuible  al  trabajo  en  el  País  Vasco  en
2008
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Objetivo:  La  falta  de  reconocimiento  del  cáncer  como  enfermedad  profesional  en  el  País  Vasco  es enorme.
Nuestro  objetivo  es estimar  el  número  de procesos  atendidos  por  cáncer  atribuibles  al  trabajo  en  el  País
Vasco en  2008,  así  como  los gastos  médicos  derivados  de  su atención  en  el Servicio  Público  Vasco  de
Salud-Osakidetza  ese mismo  an˜o.
Métodos:  El  número  de  procesos  se estimó  aplicando  las fracciones  atribuibles  al trabajo  obtenidas  en  la
literatura  cientíﬁca.  Para  el  cálculo  de los costes  se  utilizaron  datos  primarios  de  contabilidad  analítica  del
Sistema  Nacional  de  Salud  relativos  a  la  atención  especializada  (ambulatoria  e ingresos  hospitalarios),
y  fuentes  secundarias  espan˜olas  para  calcular  el  coste  de  la  atención  primaria  de  salud  y la  atención
farmacéutica.  Los  cálculos  se realizaron  por  enfermedad  y sexo.
Resultados:  En  Osakidetza,  en  2008,  hubo  1331  hospitalizaciones  y  229  consultas  a atención  ambulatoria
especializada  debidas  a cánceres  atribuibles  al  trabajo.  El  tratamiento  de  estos  procesos  supuso  más  de
10  millones  de  euros,  de  los cuales  el  64,2%  corresponden  a la  atención  especializada.  Por  tipo  de  cáncer,
el  de  bronquio  y pulmón,  fundamentalmente  en  hombres,  es el  que  implica  mayor  gasto  sanitario  (27%),
seguido  del  de  vejiga  (12,6%),  el  mesotelioma  (8,6%),  el de  colon  (7,3%)  y  el  de  estómago  (6,7%).
Conclusiones:  La  magnitud  del  cáncer  derivado  del  trabajo  en  el  País  Vasco  es muy  superior a  la  que  reﬂeja
el registro  de  enfermedades  profesionales,  lo  que obstaculiza  su prevención  y desplaza  el  correspondiente
gasto  sanitario  del sistema  de  seguridad  social  al sistema  público  de  salud.
012  S©  2∗ Corresponding author.
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IntroductionThe reporting of occupational diseases in the Basque Country
(Spain) is two to six-fold higher than in other regions of Spain
and Europe.1 Under-reporting of occupational cancer, however,
ts reserved.
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Table  1
Matrix of type of cancer, ICD-9 codes, and attributable fractions due to work according to published studies.
ICD-9 Type of cancer Doll and Peto,
USA 1981
Dreyer et al.,
Nordic Co
1997
Kogevinas
et al., EU
1998
Nurminen and
Karjalainen,
Finland 2001
Steenland
et al., USA
2003
M F M F M F M F M F
141-149, 230.0 Oral cavity and pharinx - - - - - - 2 0.5 - -
160  Nose and nasal sinuses 25 5 30 <2 39 11 24 6.7 31-43
161  Larynx 2 1 6 <1 8 0 9.3 0.5 1-20
162  Bronchus and lung 15 5 18 <1 13 3 29 5 8-19.2 2
150,  230.1 Esophagus 1 0.5 - - - - 6.4 0.2 - -
151,  230.1 Stomach 1 0.5 - - - - 10 5 - -
153,  230.3 Colon 1 0.5 - - - - 5.6 0 - -
154  Rectum 1 0.5 - - - - 3.1 0.1 - -
155  Liver and intrahepatic bile ducts 4 1 - - - - 3.5 5.3 0.4-1.1
156.0  Gallbladder - - - - - - 0.2 0.4 - -
157  Pancreas 1 0.5 - - - - 13.4 4 - -
170  Bone 4 1 - - - - 0.6 0.6 - -
172  Skin melanoma - - - - - - 4.3 0.4 - -
171,173 Skin non-melanoma 10 2 - - - - 13.1 3.8 1.2-6
158,  163 Mesothelioma 25 5 83 <1 - - 90 25 85-90 23-90
174  Female breast - - - - - - - 1.7 - -
180  Cervix uteri - - - - - - - 5.9 - -
179,182 Corpus uteri (endometrium) - - - - - - - 1.1 - -
183.0  Ovary - - - - - - - 2.1 - -
185  Prostate 1 - - - - - 6 - -
189.0, 189.1 Kidney(renal cell carcinoma) 1 0.5 - - - - 4.7 8.8 0-2.3
188  Urinary bladder 10 5 2 <1 4 0 14 0.7 7-19 3-19
191  Brain 1 0.5 2 <1 - - 10.6 1.3 - -
201  Hodgkin’s disease 1 0.5 - - - - 3.9 0 - -
- 
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158,  163 Leukemia 10 5 
: male; F: female.
s very high. Only 25 work-related cancers were compensated
rom 1995 to 2008. Among them, 15 have been reported in the
ast two years: 7 mesothelioma, 4 skin non-melanoma, 2 lym-
homas, 1 bronchus and lung and 1 nasal sinuses or nasopharyneal
ancer.1 The tumors most commonly reported in the literature
s work-related (mostly on industrial workers) are those such
s lung, bladder, sinonasal cancer, liver, mesothelioma, leukemia,
ymphoma, and non-melanoma skin cancers.2–12
There are many epidemiological studies that evaluate the
panish population in relation to occupational cancer, and sev-
ral reviews on occupational cancer in Spain have also been
ublished,13 but it is difﬁcult to obtain a comprehensive esti-
ate of work-related cancers from these studies. Following the
ead of others,8,13 we primarily use studies performed in other
omparably industrialized countries to obtain a global estimate of
ork-attributable cancer proportions in Spain (Table 1).4–6,15,16
Correctly identifying occupational cancer is a crucial task, not
nly to protect workers’ health but also for his pocket. Workers
eceive lower disability payments if the cancer is deemed non-
ccupational (60% of his/her base salary for the ﬁrst three weeks and
5% thereafter versus 100% of his/her base salary beginning on the
rst day for occupational cancers). In addition, free pharmaceutical
reatment is provided if the cancer is reported as occupational.
Identiﬁcation is the ﬁrst step to prevention. A lot of these can-
ers do not appear until retirement. As a result, a large part of their
osts are covered by the public health system, ﬁnanced by general
axes, instead of being supported by social contributions (employ-
rs and employees contributions to the social security system). In
uch conditions, the companies responsible for the occupational
xposure that caused the disease do not have to pay for the real
osts, which will be covered by taxes.
Malignant neoplasias have a major importance, given that they
re numerous, the treatment required is expensive, they cause fre-
uent work absences, both short and long term, and may  cause
remature death or a signiﬁcant decline in the quality of life. More-
ver, certain segments of the population can be more affected than- - - 13.5 3.1 - -
<1 - - 18.5 2.5 0.8-2.8
others, causing social inequalities. Finally some cancers can be eas-
ily prevented.
From the point of view of the sustainability of the social protec-
tion systems, the clariﬁcation of the assignments of costs can help
to improve the efﬁciency and efﬁcacy of the social security, occupa-
tional risk prevention and health systems. Being aware of the cost
of medical care that occupational cancer requires is particularly
useful for the sustainability of the public health system, as well as
for the adequate management of the prevention system. If these
diseases were identiﬁed as occupational, they could be included
in the global Strategies for Safety and Health at the Workplace,
and the speciﬁc prevention plans in the associated workplaces,
and, thereby, millions of euros would be saved from regional and
national budgets.
In this context, our aim is to evaluate the burden of cancer
attributable to work in the Basque Country in 2008, as well as the
health care costs derived from its treatment in the Basque Pub-
lic Health System-Osakidetza (SVS-O), using data from the analytic
accounting of the National Health System (NHS). We have recently
published on the direct health care costs associated with the lung
and bladder cancer attributable to work in Spain in 2008.14 We
now present the global burden of cancer attributable to work in
the Basque Country in 2008.
Methods
The numbers of occupational cancers in the Basque region in
2008 was derived by applying the estimates of cancer proportions
due to occupational exposures, that were obtained from studies
performed in other industrialized countries, to the databases with
clinic information of various levels of health care of the SVS-O.
These estimates do not include associated health costs, but allows
their calculation.
Numerous occupational attributable fractions have been devel-
oped, including those by Doll and Peto (1981) for the U.S.A.
population,4 Dreyer et al. (1997) for the Nordic countries,15
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ogevinas et al. (1998) for Europe,16 Nurminen and Karjalainen
2001) for Finland,6 and Steenland et al. (2003) for the U.S.A.5
Table 1). Some of the most recent estimates are detailed in United
ingdom,17 indicating that at present occupational exposures con-
inue to cause 4% of all cancers, the same percentage estimated
0 years ago by Doll and Peto. We  use the estimations of Nurminen
nd Karjailainen’s for calculation of numbers of occupational can-
ers and associated health costs for speciﬁc cancer type, due to the
uality, rigor and completeness of their approach.
Calculation of costs of the diseases was focused on direct health
are costs. For its estimation, both primary and secondary data
ources related to Spain were used. We  use the prevalence approach
o estimate the value of health care available to all patients at a
ime, regardless of when they were diagnosed. Two types of anal-
sis were performed: ﬁrst, primary data of cost of specialized care
y the NHS (hospital and specialized outpatient care) was  used
o compute costs corresponding to subjects with work attributed
ancer who were treated at Basque public hospitals; and second,
econdary data sources were used to estimate costs of both primary
ealth care and pharmaceutical care.18 The sources of information
sed were all Spanish.
Access to the statistics data in the Information System of the NHS
as made through NHS Interactive Consultation19 and through the
HS Information Repository20 upon request and being in posses-
ion of an electronic signature certiﬁcate.
Databases used were record of hospital discharges (CMBD-H)
nd record of ambulatory specialized attention (CMBD-AAE), and
he variables studied were:
 Year: 2008.
 Hospital location: Basque Country.
 Age: 25 or older.
 Sex: both.
 ICD-9-CM diagnosis: main diagnosis is coded using the ICD-9-
MC  (International Classiﬁcation of Diseases, 9th Revision, Clinical
Modiﬁcation). They can be disaggregated up to end of branch
(diagnosis coded to 5 digits). This study made consultations with
individual diagnosis as search criteria (ﬁlter) possible.
 Subjects in the CMBD-H: hospital discharges with hospitalization
at Basque public hospitals. Exclusions included subjects without
a discharge date or if the discharge date was not in 2008; dupli-
cate records; and those corresponding to subjects who were not
hospitalized (i.e, they had the same admission and discharge date
except on cases of death, transfer or voluntary discharge).
 Subjects in the CMBD-AAE: subjects treated (sessions, visits,
contacts) in specialized ambulatory attention (AAE) (day hospi-
tal, outpatients surgery and specialized home care). Exclusions
included those whose date of discharge was not in 2008 or it was
inexistent, as well as duplicate records.
 Average time of stay: average time of stay in hospital for all sub-
jects.
able 2
ccupational attributale fractions, hospital discharges and specialized ambulatory cases f
Estimations (%)
of cancer attributable
to occupational
exposure
Attributale
fractions
(%)
Number of
hospital
discharges
Hospital dis
attributable
occupation
Doll and Peto, 1981 4 17,743 709 
Kraut, 1994 4 to10 17,743 709 -1,774 
Leigh  et al., 1997 6 to10 17,743 1,064-1,774
Nurminen and Karjalainen, 2001 8.4 17,743 1,490 
Steenland et al., 2003 3.6 (2.4-4.8) 17,743 639 (426-8
WHO, 2011 19 17,743 3,371 
Median (range) 7.5 (3.6-19) 17,743 1,331 (639-
ource: own  elaboration by interactive consultation in the National Health System and Na
ocial  Policy and Equity [access April 2011]. Available from: http://pestadistico.msc.es annit. 2013;27(4):310–317
– Average cost: average cost estimated from subjects treated at
a representative sample of NHS hospitals for the corresponding
year.
– Weighted Activity Unit (in Spanish UPA): unit cost of ambula-
tory specialized attention adapting the “Weighted Activity Unit”
(UPA)21 of the hospital costs per day and disease. It has been
estimated as 75% of the cost per day hospital inpatient.22
– Weighted Activity Unit in the Basque Country in 2008 (UPA-BC
2008): unit cost for specialized outpatient services in the Basque
Country in 2008. Following formula was used to calculate the
new variable for the Basque Country:
UPA − BC 2008 =
(cost per hospital inpatient SVS − 0 2008/average stay) × 0.75
As primary data for the rest of health care costs were not
available, we assigned relative weights of primary care and phar-
maceutical care costs in relation to costs of specialized care, from
data provided by the Government of Catalonia18 (Spain) where the
health care budget for the year 2008 is distributed across the 17 rel-
evant disease categories covered by the ICD-9. Disaggregated data
are provided for specialized care (SC), primary (PC) and pharmaceu-
tical care (PhC). At our knowledge, this is the only Spanish available
source with such a degree of disaggregation. Public expenditure
on SC includes inpatient care and specialized outpatient services,
while PhC includes expenditure on prescription drugs and also
pharmaceutical expenditure supplied for outpatient care at hos-
pitals. In 2008, SC of cancer costs rises to 488,882 thousand euros,
PC, 17,745 thousand euros, and PhC, 255,409 thousand euros. From
these ﬁgures, we have obtained the following cost factors:
Cost factor for PC = PC expenditure/SC expenditure = 0.036
Cost factor for PhC = PhC expenditure/SC expenditure = 0.522
These factors were applied afterwards to the specialized care
costs for each type of cancer that was calculated with primary
sources.
Results
One in six (17%) of hospital discharges of people aged 25 years
or older in the Basque Country in 2008 were due to cancer. Speciﬁ-
cally, 17,743 hospitalizations due to cancer occurred, 9,867 in men
and 4,657 in women. Table 2 shows the number of cancer hospi-
tal discharges and specialized ambulatory cases (AAE) attributable
to work in the Basque Country in 2008, according to the pub-
lished estimates of cancer proportions attributable to occupation.
The estimates of hospital entries range from 639 to 3,371 cases,
with a median of 1,331 cases. Patients who  received outpatient care
for cancers numbered 3,058. Among those, between 110 and 581
with a median of 229, are attributable to work.
or cancer in the Basque Country, 2008, according to published studies.
charges
 cases to
al exposure
Number of
specialized
ambulatory cases
Ambulatory specialized
attention attributable cases
to occupational exposure
3,058 122
3,058 122-306
 3,058 183-306
3,058 257
52) 3,058 110 (73-147)
3,058 581
3,371) 3,058 229 (110-581)
tional Health System Database. Institute of Sanitary Information. Ministry of Health,
d http://repositorio.msc.es/risns/.
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Table  3
Hospital discharges per type of cancer and sex, in the Basque Country in 2008 attributable to occupational exposures according to Nurninen and Karjalainen estimates (2001).
Estimations of
cancer attributable to
occupational exposure
Attributale
fractions
(%)
Number of
hospital
discharges
Hospital discharges
attributable cases to
occupational exposure
Number of
specialized
ambulatory cases
Ambulatory specialized
attention attributable cases
to occupational exposure
M F M F M F M F M F
Oral cavity and pharinx 2 0.5 300 89 6 0.45 41 11 1 0.055
Nose  and nasal sinuses 24 6.7 20 13 5 1 1 - 0.24 -
Larynx  9.3 0.5 199 10 19 0.05 77 8 7 0.04
Bronchus and lung 29 5 1,013 211 294 10 34 14 10 1
Esophagus 6.4 0.2 173 26 11 0.05 32 5 2 0.01
Stomach 10 5 413 210 43 11 24 12 2 1
Colon  5.6 0 904 494 51 - 127 73 7 -
Rectum  3.1 0.1 502 234 16 0.23 72 35 2 0.035
Liver  and intrahepatic bile ducts 3.5 5.3 390 110 14 6 16 3 0.56 0.159
Gallbladder 0.2 0.4 10 34 0.02 0.14 1 3 0.002 0.012
Pancreas 13 4 215 199 29 7 7 9 1 0.315
Bone  0.6 0.6 22 16 0.13 0.1 1 2 0.006 0.012
Skin  melanoma 4.3 0.4 43 47 2 0.19 11 14 0.473 0.056
Skin  non-melanoma 13.1 3.8 153 109 20 4 81 91 11 3
Mesothelioma 90 25 82 41 74 10 3 6 3 1
Female  breast - 1.7 - 1.073 - 18 - 188 - 3
Cervix  uteri - 5.9 - 77 - 5 - 57 - 3
Corpus  uteri (endometrium) - 1.1 - 330 - 4 - 23 - 0.253
Ovary  - 2.1 - 193 - 4 - 5 - 0.105
Prostate  6 - 644 - 39 - 85 - 5
Kidney(renal cell carcinoma) 4.7 8.8 276 113 13 10 4 4 2 0.028
Urinary  bladder 14 0.7 1.382 279 196 2 12 4 0.188 0.352
Brain  10.6 1.3 206 147 22 2 3 1 0.318 0.013
Hodgkin’s disease 3.9 0 47 11 2 - 10 6 0.39 -
Non-Hodgkin’s lymphoma 13.5 3.1 164 158 22 5 38 32 5 1
Leukemia 18.5 2.5 114 110 21 3 22 18 4 0.45
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ource: own  elaboration from National Health System Database. Institute of Sanita
rom:  http://repositorio.msc.es/risns/.
Table 3 shows the number of hospital discharges by cancer site
nd sex, and the cases that, among them, are attributable to work,
sing Nurminen and Karjalainen attributable fraction estimates.
he most frequent cancers attributable to work among men  are
ung and bladder, followed by mesothelioma. Among women, the
ost frequent cancers attributable to work are breast and stomach
ancer, followed by lung, mesothelioma and kidney.
The costs associated with hospital discharges of patients with
ork- related cancers paid by the Basque Public Health System are
hown in Table 4 and total 6,556,120.9 D in 2008. These costs
re eight-fold higher in men  than in women due to the more fre-
uent occurrence of occupational cancer in men  than in women.
The work-related cancers that involve the highest cost to the
asque Public Health System per hospital entry are lung, blad-
er, mesothelioma, colon, stomach and leukemia. By sex, the cost
ttributable to male treatment ranges from 79% (stomach cancer) to
9% (bladder cancer), while the lowest cost goes from 13% (gallblad-
er cancer) to 48% (bone cancer), plus colon and Hodgkin cancers,
ith all the costs attributed to male treatment.
Although the mean cost per hospitalization is higher for men  in
lmost all the cancers, if we look at the average cost, women show
igher values for bone cancer, sinonasal, breast cancer, oral cavity
nd pharinx, larynx, leukemia, stomach and lung. Also, the average
uration of the hospitalization is higher for women than men  when
uffering from nose and nasal sinuses cancers, stomach, liver and
ntrahepatic bile ducts, gallbladder, pancreas and leukemia.
The total costs of specialized outpatients care cancer are
7,625.50 D . Costs of AAE care for work-related cancer is fourfold
igher in men  than in women. Cancers with the overall highest
AE-associated costs are skin cancer (non-melanoma), lung and
arynx.
The total specialized care cost of illness is the sum of the costs
f hospital admissions, day hospital, day surgery and home care
AAE) costs. Summing these items in Table 4, the total value isrmation. Ministry of Health, Social Policy and Equity [access April 2011]. Available
6,593,746 D . When analyzed individually and for both sexes,
lung (27%), bladder (12.6%), mesothelioma (8%), colon (8,6%), and
stomach (6,7%) are those with the highest hospital-related costs
(Table 5).
Table 5 provides the costs of specialized care (hospital dis-
charges and AAE), and the estimates costs of primary health care
and pharmaceutical care of work-related cancers, using the cost
factors (relative weights) primary care (PC) and pharmaceutical
care (PhC) cost factors, as described in the Methods section.
We estimate that the total cost of work-related cancers, in peo-
ple 25 or older, for the Basque Public Health System in 2008, is
10.26 million euros. It represents 8.54% of total Basque pub-
lic expenditure on cancer (120.15 million euros) in that year.
Hospital-related costs account for two-thirds (64.2%), followed by
pharmaceutical costs (33.5%), while primary care plays a marginal
role in the neoplasias cost (2.3%) (Table 5). The most costly cancers
are cancer of bronchus and lung (27%), mainly in men, followed
by bladder (12.6%), mesothelioma (8.6%), colon (7.3%) and stomach
(6.7%).
Discussion
In 2008, 1,331 hospital discharges of people 25 years or older
have occurred due to cancer attributable to work in the Basque
Public Health System. By contrast, 11 cases of occupational cancers
were reported by the social security system in 2008 (5 mesothe-
lioma, 3 non-melanoma skin cancers, 1 lymphoma, 1 lung and
1 sinonasal cancer).1 These data contrast remarkably with even the
most conservative estimates of work-related cancers.
The ineffectiveness of the health care and compensation sys-
tems for recognizing occupational diseases, speciﬁcally cancer,
is well-documented. Studies performed in Spain demonstrate
this underreporting. Fernández Ajuria et al. studied occupational
mortality in the Basque Country in 1987 and found 8 pleural
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Table 4
Costs of specialized ambulatory cases of cancer attributable to occupational exposure in Basque Country in 2008 (euros).
Attributable
hospital
discharges
(this study)
Average
duration of the
hospitalization
Cost per episode Total cost hospital Attributable
specialized
ambulatory
consultations
(this study)
Cost
UPA-CAPV
2008a
Total cost
Ambulatory
Specialized
Attention
M F M F M F M F M F M F M F
Oral cavity and pharinx 6 0.45 10.5 9.5 9,113.30 10,419.40 54,679.90 4,636.60 1 0.055 652.8 822.1 652.8 45.2
Nose  and nasal sinuses 5 1 8 16.3 4,410.20 6,426.00 22,051.20 6,426.00 0.24 - 416.1 295.5 99.9 -
Larynx  19 0.05 14.2 12.2 10,843.50 12,618.70 206,026.10 630.9 7 0.04 574.7 775.7 4,023.00 31
Bronchus  and lung 294 10 11.2 11.3 5,855.90 5,921.80 1,721,627.20 59,217.90 10 1 392 393.3 3,919.80 393.3
Esophagus  11 0.05 20.4 13.1 7,673.70 5,664.80 84,410.30 294.6 2 0.01 281.7 323.8 563.4 3.2
Stomach  43 11 13.6 15.1 8,115.70 8,422.80 348,974.50 92,650.80 2 1 446.6 419.2 893.1 272.5
Colon  51 - 16 19.3 9,380.60 8,888.30 478,411.80 - 7 - 439.4 345.3 3,076.00 -
Rectum  16 0.23 14.4 13.7 8,712.90 8,491.10 139,407.00 1,986.90 2 0.035 453.3 464.5 906.6 16.3
Liver  and intrahepatic bile ducts 14 6 9 10.6 8,857.80 7,577.20 124,009.00 45,463.10 0.56 0.159 736.3 534.7 412.3 85
Gallbladder  0.02 0.14 10 13 8,133.10 8,133.10 162.7 1,106.10 0.002 0.012 556.9 399.7 1.1 4.8
Pancreas  29 7 14.4 15.7 7,371.80 7,149.90 213,781.20 50,049.50 1 0.315 385.2 342.4 385.2 107.8
Bone  0.13 0.1 14.5 14.1 7,195.90 10,421.60 949.9 1,000.50 0.006 0.012 371 553.4 2.2 6.6
Skin  melanoma 2 0.19 4 4.2 4,894.80 4,772.70 9,789.60 897.3 0.473 0.056 923.1 845.4 436.6 47.3
Skin  non-melanoma 20 4 10 8.9 5,567.30 5,585.90 111,345.90 22,343.60 11 3 416.2 469.8 4,577.80 1,409.50
Mesothelioma 74 10 14.7 13 6,731.20 6,676.60 498,110.20 66,766.10 3 1 344 384 1,031.90 384
Female  breast - 18 - 4.8 - 5,285.20 - 95,134.10 - 3 -  824.1 - 2,472.40
Cervix  uteri - 5 - 12.3 - 5,904.70 - 29,523.30 - 3 -  359.7 - 1,079.10
Corpus  uteri (endometrium) - 4 - 9.6 - 6,594.40 - 26,377.60 - 0.253 -  517.7 - 131
Ovary  - 4 - 10.2 - 6,441.50 - 25,766.20 - 0.105 -  472.6 - 49.6
Prostate  39 - 7.4 - 5,768.20 - 224,960.30 - 5 587.4 - 2,937.00 -
Kidney(renal cell carcinoma) 13 10 8.1 7.3 8,266.00 7,344.00 107,458.00 73,439.70 2 0.028 448.4 470.1 896.7 13.2
Urinary  bladder 196 2 7 6.6 4,209.70 4,137.90 825,102.80 8,275.70 0.188 0.352 763.3 749.5 143.5 263.8
Brain  22 2 11.6 11.8 8,445.70 8,467.00 185,806.40 16,934.00 0.318 0.013 544.8 537.7 173.3 7
Hodgkin’s  disease 2 - 13.1 12.2 10,256.00 8,094.50 20,512.10 - 0.39 - 586.9 498.4 228.9 -
Non-Hodgkin’s lymphoma 22 5 15.5 13.1 8,856.10 8,315.80 194,835.10 41,579.00 5 1 427.5 477.4 2,137.60 477.4
Leukemia  21 3 14.7 22.7 12,746.70 15,176.50 267,680.70 45,529.50 4 0.45 650.3 500.8 2,601.30 225.4
Total  899 103 5,840,091.8 716,029.00 64 15 30,100.00 7,525.50
Source: own  elaboration from National Health System Database. Institute of Sanitary Information. Ministry of Health, Social Policy and Equity [access April 2011]. Available from: http://repositorio.msc.es/risns/.
a (Cost per hospital inpatient SVS-0 2008/average stay) × 0,75.
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Table  5
Total sanitary costs per type of occupational cancer in Basque Country in 2008 (euros).
Specialized care costa Prymary care costb Pharmacy costc Sanitary cost per disease
Oral cavity and pharinx 60,014.52 2,160.52 31,207.55 93,382.60
Nose  and nasal sinuses 28,577.13 1,028.78 14,860.11 44,466.01
Larynx  210,711.07 7,585.60 109,569.76 327,866.43
Bronchus and lung 1,785,158.12 64,265.69 928,282.22 2,777,706.04
Esophagus 85,271.51 3,069.77 44,341.19 132,682.48
Stomach 442,790.88 15,940.47 230,251.26 688,982.61
Colon  481,487.80 17,333.56 250,373.66 749,195.01
Rectum  142,316.71 5,123.40 74,004.69 221,444.81
Liver  and intrahepatic bile ducts 169,969.37 6,118.90 88.,384.07 264,472.34
Gallbladder 1,274.67 45.89 662.83 1,983.39
Pancreas 264,323.70 9,515.65 137,448.33 411,287.68
Bone  1,959.20 70.53 1,018.79 3,048.52
Skin  melanoma 11,170.92 402.15 5,808.88 17,381.95
Skin  non-melanoma 139,676.75 5,028.36 72,631.91 217,337.02
Mesothelioma 566,292.14 20,386.52 294,471.91 881,150.56
Female  breast 97,606.41 3,513.83 50,755.33 151,875.58
Cervix  uteri 30,602.38 1,101.69 15,913.24 47,617.30
Corpus  uteri (endometrium) 26,508.62 954.31 13,784.48 41,247.41
Ovary 25,815.79 929.37 13,424.21 40,169.38
Prostate  227,897.32 8,204.30 118,506.61 354,608.23
Kidney  (renal cell carcinoma) 181,807.57 6,545.07 94,539.94 282,892.58
Urinary  bladder 833,785.89 30,016.29 433,568.66 1,297,370.84
Brain  202,920.64 7,305.14 105,518.73 315,744.51
Hodgkin’s disease 20,740.97 746.67 10,785.30 32,272.95
Non-Hodgkin’s lymphoma 239,029.17 8,605.05 124,295.17 371,929.39
Leukemia 316,036.95 11,377.33 164,339.22 491,753.50
Total  6,593,746.22 237,374.86 3.428.748,03 10,259,869.12
Source: own  elaboration from National Health System Database. Institute of Sanitary Information. Ministry of Health, Social Policy and Equity [access April 2011]. Available
from:  http://repositorio.msc.es/risns/.
a Sumatory of the columms 8, 9, 14 y 15 from Table 4.
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fb Cost factor for primary care = 0.036 × specialized care cost.
c Cost factor for pharmacy = 0.522 × specialized care cost.
esotheliomas reported in the Basque Cancer Registry, but only 2
ad been evaluated in the Disabilities Medical Assessment Units,
nd none were recognize as occupational by the social security
ystem,23 while pleural mesothelioma is an occupational health
vent inherent to work, and it is highly unlikely to develop with-
ut an occupational exposure. García and Gadea (2007) estimate
he work-related deaths caused by malignant neoplasias in the
asque Country in 2004 to be 460.24 It has also been estimated
hat 25.4% of the Spanish working population in 2004 was exposed
o carcinogens at their workplace.13
Reasons for under-reporting are legion and include the classiﬁ-
ation of occupational diseases as common diseases, the intrinsic
cientiﬁc difﬁculty to catalogue a disease as occupational,25 the
gnorance of the health care professionals about occupational risk
actors,26 the disinterest in prevention by the health care system,
nd the resistance by employers to accept the classiﬁcation of a
isease as work-related.27
To estimate the burden of work-related cancer, we have used the
ublished estimations of attributable fractions, speciﬁcally those
f Leigh et al.,28 Doll and Peto (1981),4 Steenland et al.5 for the
.S. population; the estimates for the Nordic countries,15 and for
he Finland;6 and estimates for Europe16 and by WHO  (WHO,
011).29 As we said in the introduction, there are many Spanish
pidemiological studies that evaluate the population in relation to
ccupational cancer, but it is difﬁcult to obtain attributable frac-
ions from these studies. This fact, coupled with the poor quality
f the system of occupational cancer, justiﬁes the use of other
tudies. The estimates vary in large part due to incomplete data,
ut are nonetheless useful, recognizing limitations. The utilization
f attributable fractions in studies performed in other countries
ay  be a limitation of our study, although they have been used
n other economically advanced countries.30,31 To be conservative,
e use the median value of a wide range of work-attributable
ractions. We  also used the organ-speciﬁc estimates for cancer fromthe most complete and rigorous analysis of this issue, the study
from Finland.6 Even so, not all cancers are included in the Finnish
study, and it is likely that we underestimated the number of cases
of work-attributable cancers.
As in other studies,8,13 we have found that most work-related
cancers occur in men, and that lung and urinary bladder cancers are
the most frequent cancers. There is an awareness of the existence
of many agents associated to these two cancers, including asbestos,
silica, metals, radiation, combustion products, aromatic amines,
and other exposures. Other important occupational cancers are
mesothelioma, caused almost exclusively by exposure to asbestos,
sinonasal cancer, caused by exposure to wood dust, metals and
formaldehyde, and leukemia and lymphoma, caused by solvents,
insecticides and other chemicals.
Regarding to medical costs generated by these cases of occupa-
tional cancer, we chose the prevalence approach to estimate the
value of health care available to all patients at a time, regardless
of when they were diagnosed,32–34 because it permits analysis of
reliable available data that require fewer forecasting assumptions
than the incidence method. It must also be emphasized that the
sources of information used were all Spanish. We use as a primary
source the data from the analytical accounting of the NHS to cal-
culate the health care cost of occupational cancers attended by
the Basque Public Health System. We  analyzed the direct health
costs, which include the medical services used for diagnosis and
treatment of the disease. We  did not analyze the indirect costs,
which correspond to the productivity losses caused by the pre-
mature mortality and morbidity associated with these neoplasias,
as well as those from the corresponding sick leaves (both tempo-
rary and permanent). Non-health costs such as remunerated and
non-remunerated caregivers have not been included either. Addi-
tionally, only those cancers with enough scientiﬁc evidence of their
occupational origin have been considered. This is, therefore, an
underestimate of the total direct health care costs of work-related
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ancers. Even so, work-related cancers account for more than 10
illion euros, or 8.54% of total Basque public expenditure on cancer
are in 2008.
The limitations of our calculation of the costs of occupational
ancer are related to the completeness of the primary data on
he cost of specialized care and the use of secondary sources for
he computation of the primary care and pharmaceutical costs.
egarding the primary sources the coverage of the information
ystem for hospitalizations is 100%. While in the cases attended
n ambulatory specialized attention (AAE), the coverage is 100% for
he surgical activity, but only 46.7% in the medical activity of the day
ospital, according to the Statistics of Sanitary Establishments.22
This limitation leads to an underestimation of the total expen-
iture for these diseases, which is ampliﬁed in calculating costs
f primary care and pharmaceutical treatment, since calculation of
he latter are based in part on the former. As described in the Meth-
ds section, we have combined primary and secondary sources
ue to the lack of primary sources for all the components of the
irect costs.34 It must be emphasized that the difﬁculties to access
rimary data are not exclusive for Spain. Other countries show a
imilar situation. Thus, a Commission of the French Senate respon-
ible for a report similar to this study acknowledged the lack of a
atabase that included the health costs according to diseases and
hich permitted a reliable calculation of the costs of work related
iseases.35 In our view, the use of the Catalonian Health Budget
or the same year minimizes these errors, since their reﬂect ﬁg-
res from one of the Spanish regions. However, when using data
rom Catalonia as a base for the Basque Country we are assuming
hat there are no substantial differences between the health care
osts structure in both regions. Nevertheless, several authors have
ointed to the variability in health care costs across the Spanish
HS, which could be due to differences in factor prices, produc-
ivity, efﬁciency or inappropriate use of services, among other
actors.36,37
An advantage of our method was that estimates were derived
rom linear calculations, which we have attempted with trans-
arency. As a result, any estimate in our tables can be adjusted
or a different region in Spain or for a different attributable
raction.
Carcinogens at the workplace play an important role on the
dentiﬁcation and prevention of all the carcinogens,2 as they were
he ﬁrst identiﬁed and represent a high percentage of the total. All
he cancers they cause are preventable. It is important to identify
nd prevent the carcinogens at workplaces, because the advantages
f identiﬁcation and adequate proceeding beneﬁt the society as
 whole, as the general population is also exposed to these sub-
tances (for instance, benzene, asbestos, diesel motors exhausts,
tc.).
Most diseases, including cancers, are not recognized as occu-
ational diseases even if they result from occupational exposures.
valuating the under-recognition of occupational diseases remains
omplex, since the only data available are communicated by social
ecurity funds that only take into account the very few cases that
ffectively led to indemniﬁcation. Cancer is a paradigmatic case of
his, as can be derived from its minimal reporting as occupational
isease, as shown in this paper. This highly impedes the prevention
f occupational cancer, given that identiﬁcation is one of the main
ssues for its adequate management.
Moreover, the treatment of occupational cancers leads to sub-
tantial health care costs which are currently shifted from the social
ecurity system to the tax-ﬁnanced public health system. An impor-
ant consequence of this transfer is that the companies, which are
esponsible for conditions that led to the cancers, do not have to
ay associated costs and, further, have no incentive to take preven-
ive actions to reduce risk of cancer. The public health system is
urdened by this transfer of costs.nit. 2013;27(4):310–317
What is known on the topic?
The magnitude of the occupational health burden is very
large and, therefore, involves a high cost to workers, employ-
ers and society as a whole. However, there is a serious
problem in Spain with the recognition of occupational cancers.
Although the Spanish list of occupational diseases includes
many  agents that are associated with certain types of cancer,
the number of those recognized as professionals is virtually
nonexistent. In the past few years the economics of occupa-
tional health area has emerged as a key area of research.
What does this study add to the literature?
This is the ﬁrst study in Spain that estimates the burden of
cancer attributable to work in the Basque Country in 2008, as
well as the health care costs derived from its treatment in the
Basque Public Health System-Osakidetza. The sources of infor-
mation used were all Spanish. Economic evaluation is clearly
relevant for future preventive and health promotion programs.
This paper will provide information to demonstrate to decision
makers in companies and government the necessity for work-
places interventions and adequate provisions of occupational
health services. Furthermore, it will show how a proportion
of medical costs are being shifted from social security to the
tax-ﬁnanced public health system.
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